JP2021519063A5 - - Google Patents

Info

Publication number
JP2021519063A5
JP2021519063A5 JP2020551300A JP2020551300A JP2021519063A5 JP 2021519063 A5 JP2021519063 A5 JP 2021519063A5 JP 2020551300 A JP2020551300 A JP 2020551300A JP 2020551300 A JP2020551300 A JP 2020551300A JP 2021519063 A5 JP2021519063 A5 JP 2021519063A5
Authority
JP
Japan
Prior art keywords
population
cells
proportion
marker
expressed
Prior art date
Application number
JP2020551300A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021519063A (ja
JPWO2019180279A5 (https=
Filing date
Publication date
Priority claimed from GBGB1804701.9A external-priority patent/GB201804701D0/en
Application filed filed Critical
Publication of JP2021519063A publication Critical patent/JP2021519063A/ja
Publication of JP2021519063A5 publication Critical patent/JP2021519063A5/ja
Publication of JPWO2019180279A5 publication Critical patent/JPWO2019180279A5/ja
Priority to JP2024020808A priority Critical patent/JP2024073435A/ja
Pending legal-status Critical Current

Links

JP2020551300A 2018-03-23 2019-03-25 異種ターゲティング構築物を発現するリンパ球 Pending JP2021519063A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024020808A JP2024073435A (ja) 2018-03-23 2024-02-15 異種ターゲティング構築物を発現するリンパ球

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1804701.9A GB201804701D0 (en) 2018-03-23 2018-03-23 Lymphocytes expressing heterologous targeting constructs
GB1804701.9 2018-03-23
PCT/EP2019/057469 WO2019180279A1 (en) 2018-03-23 2019-03-25 Lymphocytes expressing heterologous targeting constructs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024020808A Division JP2024073435A (ja) 2018-03-23 2024-02-15 異種ターゲティング構築物を発現するリンパ球

Publications (3)

Publication Number Publication Date
JP2021519063A JP2021519063A (ja) 2021-08-10
JP2021519063A5 true JP2021519063A5 (https=) 2022-03-30
JPWO2019180279A5 JPWO2019180279A5 (https=) 2022-03-30

Family

ID=62068083

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020551300A Pending JP2021519063A (ja) 2018-03-23 2019-03-25 異種ターゲティング構築物を発現するリンパ球
JP2024020808A Pending JP2024073435A (ja) 2018-03-23 2024-02-15 異種ターゲティング構築物を発現するリンパ球

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024020808A Pending JP2024073435A (ja) 2018-03-23 2024-02-15 異種ターゲティング構築物を発現するリンパ球

Country Status (15)

Country Link
US (1) US20210015867A1 (https=)
EP (2) EP4015525A3 (https=)
JP (2) JP2021519063A (https=)
KR (1) KR20220029292A (https=)
CN (1) CN112513067A (https=)
AU (2) AU2019239705B9 (https=)
BR (1) BR112020019143A2 (https=)
CA (1) CA3094766A1 (https=)
EA (1) EA202092261A1 (https=)
GB (1) GB201804701D0 (https=)
IL (2) IL277517B2 (https=)
MX (3) MX2020009859A (https=)
MY (1) MY208877A (https=)
PH (1) PH12020551538A1 (https=)
WO (1) WO2019180279A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3150224A1 (en) 2019-09-10 2021-03-18 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
GB202013962D0 (en) 2020-09-04 2020-10-21 Gammadelta Therapeutics Ltd Immunotherapy composition
CN115381965B (zh) * 2022-09-01 2023-03-14 广东龄值生物科技有限公司 一种γδT细胞功能化的磁性微球、制备方法及其用途

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
EP1291360A1 (en) 1991-12-13 2003-03-12 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
CN1294148C (zh) 2001-04-11 2007-01-10 中国科学院遗传与发育生物学研究所 环状单链三特异抗体
KR20060041205A (ko) 2003-07-01 2006-05-11 이뮤노메딕스, 인코오포레이티드 양특이성 항체들의 다가 담체들
EP1660186B1 (en) 2003-08-18 2013-12-25 MedImmune, LLC Humanization of antibodies
WO2005035575A2 (en) 2003-08-22 2005-04-21 Medimmune, Inc. Humanization of antibodies
JP2008512352A (ja) 2004-07-17 2008-04-24 イムクローン システムズ インコーポレイティド 新規な四価の二重特異性抗体
KR20130108481A (ko) 2005-08-19 2013-10-02 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
US8940707B2 (en) 2010-10-28 2015-01-27 Viropharma Incorporated Maribavir isomers, compositions, methods of making and methods of using
CN103635573B (zh) 2011-05-19 2016-05-11 分子医学研究所 包含γδT细胞的淋巴细胞系、其组合物及生产方法
GB201506423D0 (en) * 2015-04-15 2015-05-27 Tc Biopharm Ltd Gamma delta T cells and uses thereof
WO2016081518A2 (en) 2014-11-17 2016-05-26 Adicet Bio, Inc. Engineered gamma delta t-cells
GB201507368D0 (en) * 2015-04-30 2015-06-17 Ucl Business Plc Cell
AU2016274633B2 (en) 2015-06-09 2022-04-21 Gammadelta Therapeutics Ltd Methods for the production of TCR gamma delta+ T cells
EP4148124A1 (en) 2015-10-30 2023-03-15 Cancer Research Technology Limited Expansion of non-haematopoietic tissue-resident gamma delta t cells and uses of these cells
EP3708587B1 (en) * 2015-11-27 2024-05-22 Cartherics Pty. Ltd. Genetically modified cells and uses thereof
US12060394B2 (en) * 2016-04-28 2024-08-13 The Trustees Of Dartmouth College Nucleic acid constructs for co-expression of chimeric antigen receptor and transcription factor, cells containing and therapeutic use thereof
EP3454870A4 (en) 2016-05-12 2020-03-04 Adicet Bio Inc. METHOD FOR SELECTIVE EXPANSION OF GAMMA DELTA T CELL POPULATIONS AND COMPOSITIONS THEREOF
CN109844099B (zh) * 2016-07-25 2024-01-02 美国政府(由卫生和人类服务部的部长所代表) 产生经修饰的自然杀伤细胞的方法及使用方法
GB201707048D0 (en) 2017-05-03 2017-06-14 King S College London Expansion of gamma delta cells, compositions, and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2021519063A5 (https=)
Wainwright et al. Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR.
Al-Betar et al. Island-based harmony search for optimization problems
Phan et al. Stock return forecasting: Some new evidence
JP2013516431A5 (https=)
EP4235549A3 (en) Rapid distributed consensus on blockchain
JP2015158565A5 (https=)
JP2020507222A5 (https=)
JP2018501356A5 (https=)
GB2564596A8 (en) Quantum processor and its use for implementing a neural network
JP2019212805A5 (https=)
JP2015505089A5 (https=)
JP2014063186A5 (https=)
JP2017512848A5 (https=)
JP2021067755A5 (https=)
JP2015041624A5 (https=)
JP2018529964A5 (https=)
JP2012084862A5 (https=)
JP2017145235A5 (https=)
WO2020086362A3 (en) Relativistic quantum computer / quantum gravity computer
EP3999696C0 (en) GYPSUM INTERLOCKING SURFACE BUILDING PRODUCTS, MANUFACTURING METHODS
JP2019506134A5 (https=)
MX2020010410A (es) Empaquetado de oligonucleotidos en particulas similares a virus.
JPWO2019180279A5 (https=)
JP2016516274A5 (https=)